Hana Pharm. Co., Ltd. Logo

Hana Pharm. Co., Ltd.

Pharmaceutical firm specializing in anesthetics and narcotic analgesics for global markets.

293480 | KO

Overview

Corporate Details

ISIN(s):
KR7293480000
LEI:
Country:
South Korea
Address:
경기도 화성시 향남읍 제약단지로 13-39, 화성시
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Hana Pharm Co., Ltd. is a pharmaceutical company specializing in the development, manufacturing, and distribution of specialty medicines. The company has a strong focus on anesthetics and narcotic analgesics, offering a comprehensive product portfolio that also includes antiemetics and antibiotics. Operating both domestically in South Korea and internationally, Hana Pharm is committed to innovation and quality, with significant investment in Good Manufacturing Practice (GMP) facilities. Its research and development pipeline includes novel products such as Byfavo Inj., an ultra-short-acting anesthetic and sedative, and a new multi-functional MRI contrast medium. The company went public in 2018 and continues to expand its market presence through ongoing research and strategic product development.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-09-04 00:00
Post-Annual General Meeting Information
임시주주총회결과
Korean 7.1 KB
2025-08-20 00:00
Pre-Annual General Meeting Information
주주총회소집공고
Korean 83.8 KB
2025-08-14 00:00
Interim Report
반기보고서 (2025.06)
Korean 1.1 MB
2025-07-23 00:00
Pre-Annual General Meeting Information
주주총회소집결의
Korean 8.3 KB
2025-07-23 00:00
Pre-Annual General Meeting Information
주주명부폐쇄기간또는기준일설정
Korean 4.3 KB
2025-06-17 00:00
Major Shareholding Notification
임원ㆍ주요주주특정증권등소유상황보고서
Korean 24.2 KB
2025-05-15 00:00
Quarterly Report
분기보고서 (2025.03)
Korean 1.1 MB
2025-04-23 00:00
Regulatory News Service
신규시설투자등
Korean 8.4 KB
2025-03-24 00:00
Post-Annual General Meeting Information
정기주주총회결과
Korean 24.8 KB
2025-03-14 00:00
Audit Report / Information
감사보고서제출
Korean 11.4 KB
2025-03-14 00:00
Annual / Quarterly Financial Statement
사업보고서 (2024.12)
Korean 501.3 KB
2025-03-07 00:00
Pre-Annual General Meeting Information
주주총회소집공고
Korean 158.7 KB
2025-02-28 00:00
Remuneration Information
기타경영사항(자율공시)
Korean 5.1 KB
2025-02-21 00:00
Pre-Annual General Meeting Information
주주총회소집결의
Korean 11.6 KB
2025-02-21 00:00
Notice of Dividend Amount
현금ㆍ현물배당결정
Korean 9.0 KB

Automate Your Workflow. Get a real-time feed of all Hana Pharm. Co., Ltd. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Hana Pharm. Co., Ltd.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Hana Pharm. Co., Ltd. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

LISATA THERAPEUTICS, INC. Logo
Oncology firm with a platform for more effective, targeted delivery of anti-cancer drugs.
United States of America
LSTA
LIXTE BIOTECHNOLOGY HOLDINGS, INC. Logo
Developing novel PP2A inhibitors to enhance cancer therapies and overcome treatment resistance.
United States of America
LIXT
Longeveron Inc. Logo
Develops cell therapies for Alzheimer's, aging frailty, and rare infant heart defects.
United States of America
LGVN
Lonza Group AG Logo
A leading CDMO for pharma, biotech & nutrition, providing end-to-end development & manufacturing.
Switzerland
LONN
Lyell Immunopharma, Inc. Logo
Develops durable CAR T-cell therapies for solid tumors & blood cancers by reprogramming T-cells.
United States of America
LYEL
Lyra Therapeutics, Inc. Logo
Developing localized, long-acting therapies for chronic rhinosinusitis (CRS).
United States of America
LYRA
Lytix Biopharma AS Logo
Develops oncolytic peptide immunotherapies that kill cancer and stimulate an anti-tumor response.
Norway
LYTIX
MaaT Pharma Logo
Developing gut microbiome therapies to improve survival for cancer patients.
France
MAAT
Mabion S.A. Logo
Global CDMO providing end-to-end services for developing and manufacturing complex biologic drugs.
Poland
MAB
MACROGENICS INC Logo
Biopharma firm developing innovative antibody-based therapeutics for cancer treatment.
United States of America
MGNX

Talk to a Data Expert

Have a question? We'll get back to you promptly.